Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| oligodendrocyte precursor cell | 13 studies | 66% ± 13% | |
| glutamatergic neuron | 12 studies | 67% ± 17% | |
| GABAergic neuron | 11 studies | 65% ± 25% | |
| neuron | 6 studies | 40% ± 17% | |
| interneuron | 6 studies | 83% ± 10% | |
| glial cell | 5 studies | 44% ± 25% | |
| retinal cone cell | 5 studies | 50% ± 25% | |
| endothelial cell | 4 studies | 39% ± 21% | |
| granule cell | 4 studies | 42% ± 9% | |
| differentiation-committed oligodendrocyte precursor | 3 studies | 46% ± 3% | |
| GABAergic interneuron | 3 studies | 77% ± 11% | |
| microglial cell | 3 studies | 39% ± 18% | |
| amacrine cell | 3 studies | 32% ± 10% | |
| GABAergic amacrine cell | 3 studies | 65% ± 15% | |
| glycinergic amacrine cell | 3 studies | 31% ± 12% | |
| retinal ganglion cell | 3 studies | 46% ± 27% | |
| Schwann cell | 3 studies | 53% ± 24% | |
| oligodendrocyte | 3 studies | 32% ± 23% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 15 studies | 44% ± 23% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 94% | 759.43 | 2489 / 2642 | 70% | 2.48 | 495 / 705 |
| intestine | 81% | 1022.56 | 786 / 966 | 0% | 0.00 | 2 / 527 |
| esophagus | 76% | 804.39 | 1103 / 1445 | 4% | 0.11 | 7 / 183 |
| prostate | 69% | 305.70 | 170 / 245 | 0% | 0.01 | 2 / 502 |
| bladder | 67% | 283.33 | 14 / 21 | 1% | 0.01 | 4 / 504 |
| heart | 54% | 306.34 | 468 / 861 | 0% | 0 | 0 / 0 |
| kidney | 40% | 107.93 | 36 / 89 | 14% | 0.44 | 124 / 901 |
| pancreas | 46% | 88.52 | 150 / 328 | 4% | 0.13 | 8 / 178 |
| ovary | 11% | 43.50 | 20 / 180 | 33% | 0.82 | 144 / 430 |
| stomach | 42% | 266.33 | 151 / 359 | 2% | 0.03 | 5 / 286 |
| adrenal gland | 12% | 29.60 | 32 / 258 | 20% | 0.41 | 45 / 230 |
| thymus | 25% | 59.06 | 166 / 653 | 5% | 0.11 | 32 / 605 |
| skin | 29% | 68.99 | 516 / 1809 | 2% | 0.05 | 9 / 472 |
| breast | 24% | 69.42 | 109 / 459 | 1% | 0.02 | 6 / 1118 |
| adipose | 23% | 72.34 | 278 / 1204 | 0% | 0 | 0 / 0 |
| uterus | 18% | 69.66 | 31 / 170 | 3% | 0.06 | 16 / 459 |
| blood vessel | 21% | 82.69 | 286 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 20% | 0.71 | 9 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 7% | 0.12 | 2 / 29 |
| lung | 3% | 4.57 | 15 / 578 | 3% | 0.13 | 40 / 1155 |
| liver | 3% | 5.03 | 7 / 226 | 0% | 0.00 | 1 / 406 |
| peripheral blood | 2% | 4.95 | 15 / 929 | 0% | 0 | 0 / 0 |
| spleen | 1% | 1.00 | 2 / 241 | 0% | 0 | 0 / 0 |
| muscle | 0% | 0.34 | 2 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_1902742 | Biological process | apoptotic process involved in development |
| GO_0043652 | Biological process | engulfment of apoptotic cell |
| GO_0070782 | Biological process | phosphatidylserine exposure on apoptotic cell surface |
| GO_0005886 | Cellular component | plasma membrane |
| Gene name | XKR4 |
| Protein name | XK-related protein 4 (hXKR4) [Cleaved into: XK-related protein 4, processed form] |
| Synonyms | KIAA1889 XRG4 |
| Description | FUNCTION: [XK-related protein 4, processed form]: Phospholipid scramblase that promotes phosphatidylserine exposure on apoptotic cell surface . Phosphatidylserine is a specific marker only present at the surface of apoptotic cells and acts as a specific signal for engulfment . . |
| Accessions | Q5GH76 ENST00000327381.7 |